دورية أكاديمية
Comparative Analysis of Subclassification Systems in Patients with Intermediate-Stage Hepatocellular Carcinoma (Barcelona Clinic Liver Classification B) Receiving Systemic Therapy
| العنوان: | Comparative Analysis of Subclassification Systems in Patients with Intermediate-Stage Hepatocellular Carcinoma (Barcelona Clinic Liver Classification B) Receiving Systemic Therapy |
|---|---|
| المؤلفون: | Ielasi L., Stefanini B., Conti F., Tonnini M., Tortora R., Magini G., Sacco R., Pressiani T., Trevisani F., Foschi F. G., Piscaglia F., Granito A., Tovoli F. |
| المساهمون: | Ielasi L., Stefanini B., Conti F., Tonnini M., Tortora R., Magini G., Sacco R., Pressiani T., Trevisani F., Foschi F.G., Piscaglia F., Granito A., Tovoli F. |
| سنة النشر: | 2024 |
| المجموعة: | IRIS Università degli Studi di Bologna (CRIS - Current Research Information System) |
| مصطلحات موضوعية: | Barcelona Clinic Liver Classification, BCLC B, hepatocellular carcinoma, intermediate stage, subclassification, systemic therapy |
| الوصف: | Background: Intermediate-stage hepatocellular carcinoma (BCLC B HCC) occurs in a heterogeneous group of patients and can be addressed with a wide spectrum of treatments. Consequently, survival significantly varies among patients. In recent years, several subclassification systems have been proposed to stratify patients’ prognosis. We analyzed and compared these systems (Bolondi, Yamakado, Kinki, Wang, Lee, and Kim criteria) in patients undergoing systemic therapy. Methods: We considered 171 patients with BCLC B HCC treated with sorafenib as first-line systemic therapy in six Italian centers from 2010 to 2021 and retrospectively applied the criteria of six different subclassification systems. Results: Except for the Yamakado criteria, all the subclassification systems showed a statistically significant correlation to overall survival (OS). In the postestimation analysis, the Bolondi criteria (OS of subgroups 22.5, 11.9, and 6.6 mo, respectively; C-index 0.586; AIC 1338; BIC 1344) and the Wang criteria (OS of subgroups 20.6, 11.9, and 7.0, respectively; C-index 0.607; AIC 1337; BIC 1344) presented the best accuracy. Further analyses of these two subclassification systems implemented with the prognostic factor of alpha-fetoprotein (AFP) > 400 ng/mL have shown an increase in accuracy for both systems (C-index 0.599 and 0.624, respectively). Conclusions: Intermediate-stage subclassification systems maintain their predictive value also in the setting of systemic therapy. The Bolondi and Wang criteria showed the highest accuracy. AFP > 400 ng/mL enhances the performance of these systems. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | ELETTRONICO |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/38275831; info:eu-repo/semantics/altIdentifier/wos/WOS:001151845200001; volume:31; issue:1; firstpage:547; lastpage:557; numberofpages:11; journal:CURRENT ONCOLOGY; https://hdl.handle.net/11585/955558Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85183193387; https://www.mdpi.com/1718-7729/31/1/38Test |
| DOI: | 10.3390/curroncol31010038 |
| الإتاحة: | https://doi.org/10.3390/curroncol31010038Test https://hdl.handle.net/11585/955558Test https://www.mdpi.com/1718-7729/31/1/38Test |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.10513CBA |
| قاعدة البيانات: | BASE |
| DOI: | 10.3390/curroncol31010038 |
|---|